These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30397837)

  • 41. Is it Worth CANVASing for CREDENCE? A Benefit-risk Analysis.
    Sinha B; Ghosal S
    Curr Diabetes Rev; 2020; 16(5):509-514. PubMed ID: 31652114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Studies With Molecules Within the Same Class, but With Different Designs Yield Different Results. EMPA-REG, CANVAS and DECLARE.
    Gippini A; Prado A
    Rev Esp Cardiol (Engl Ed); 2019 Dec; 72(12):1095-1096. PubMed ID: 31455542
    [No Abstract]   [Full Text] [Related]  

  • 43. [Analysis of cardiovascular safety of novel glucose-lowering medications].
    Mkrtumyan AM; Markova TN; Mishchenko NK
    Kardiologiia; 2019 Jul; 59(7):76-83. PubMed ID: 31322093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
    Vallon V; Thomson SC
    Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
    [No Abstract]   [Full Text] [Related]  

  • 45. Canagliflozin and Cardiovascular disease- results of the CANVAS trial.
    Shah SR; Najim NI; Abbasi Z; Fatima M; Jangda AA; Shahnawaz W; Shahid M; Shah SA
    J Community Hosp Intern Med Perspect; 2018; 8(5):267-268. PubMed ID: 30357039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Med; 2017 Jun; 130(6S):S51-S56. PubMed ID: 28526185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
    Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
    Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus.
    Watts NB; Bilezikian JP; Usiskin K; Edwards R; Desai M; Law G; Meininger G
    J Clin Endocrinol Metab; 2016 Jan; 101(1):157-66. PubMed ID: 26580237
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
    Skelley JW; Carter BS; Roberts MZ
    Vasc Health Risk Manag; 2018; 14():419-428. PubMed ID: 30573964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
    Dekkers CCJ; Gansevoort RT; Heerspink HJL
    Curr Diab Rep; 2018 Mar; 18(5):27. PubMed ID: 29589183
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program.
    Weir MR; Slee A; Sun T; Balis D; Oh R; de Zeeuw D; Perkovic V
    Clin Kidney J; 2021 May; 14(5):1396-1402. PubMed ID: 34221371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of EMPA-REG OUTCOME
    Naing S; Poliyedath A; Khandelwal S; Sigala T
    Postgrad Med; 2016 Nov; 128(8):822-827. PubMed ID: 27701934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Nov; 121():204-214. PubMed ID: 27744129
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
    Marx N; McGuire DK; Perkovic V; Woerle HJ; Broedl UC; von Eynatten M; George JT; Rosenstock J
    Diabetes Care; 2017 Sep; 40(9):1144-1151. PubMed ID: 28830955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME].
    Scheen AJ
    Rev Med Liege; 2019 Apr; 74(4):185-191. PubMed ID: 30997967
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EMPA-REG OUTCOME: The Endocrinologist's Point of View.
    Perreault L
    Am J Cardiol; 2017 Jul; 120(1S):S48-S52. PubMed ID: 28606344
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiac effects of SGLT2 inhibitors: the sodium hypothesis.
    Bertero E; Prates Roma L; Ameri P; Maack C
    Cardiovasc Res; 2018 Jan; 114(1):12-18. PubMed ID: 29016751
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mortality Reduction in EMPA-REG OUTCOME Trial: Beyond the Antidiabetes Effect.
    Suissa S
    Diabetes Care; 2018 Feb; 41(2):219-223. PubMed ID: 29358464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New antihyperglycaemic agents and cardiovascular disease: let's be optimistic.
    Pafili K; Rizzo M; Papanas N
    Curr Opin Cardiol; 2018 Jul; 33(4):444-454. PubMed ID: 29702499
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.